- Home
- NYC vs IGC Comparison
NYC vs IGC Comparison
Compare NYC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | IGC |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 28.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NYC | IGC |
|---|---|---|
| Price | $11.38 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 6.7K | ★ 448.1K |
| Earning Date | 03-18-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,688,000.00 | $1,106,000.00 |
| Revenue This Year | $8.40 | $3.54 |
| Revenue Next Year | $1.62 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.03 | $0.25 |
| 52 Week High | $16.30 | $0.50 |
Technical Indicators
Market Signals| Indicator | NYC | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 71.14 | 38.03 |
| Support Level | $9.93 | $0.29 |
| Resistance Level | $11.99 | $0.30 |
| Average True Range (ATR) | 0.75 | 0.01 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 81.17 | 7.49 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.